The abstract is read at the publisher; the summary is JClub's.
Targeted polymeric nanoparticles that deliver nucleic acids are reviewed as a next-generation platform for localized in vivo production of therapeutic antibodies.
- Why it matters: Conventional antibody therapies face high costs, repeated dosing burdens, and unwanted side effects, motivating approaches that can produce proteins locally and more controllably.
- What they did: The review analyzes nanoparticle design across four components: polymer matrix types, genetic payloads for antibody expression, linker chemistries (covalent, stimuli-responsive, or non-covalent), and targeting tools (antibodies/fragments, peptides, or aptamers).
- The result: The paper reports that combining gene therapy with nanomedicine can reduce immune responses and is promising for treating cancer, infections, and autoimmune diseases, with in vivo validation discussed in relation to antibody mechanisms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.